Valuation: Personalis, Inc.

Market Cap 1.57B 1.37B 1.27B 1.16B 2.21B 151B 2.25B 15.09B 5.92B 74B 5.91B 5.78B 255B P/E 2026 *
-14.7x
P/E 2027 * -16.6x
Enterprise Value 1.4B 1.22B 1.12B 1.03B 1.96B 134B 1.99B 13.39B 5.26B 65.65B 5.24B 5.13B 226B EV / Sales 2026 *
17.7x
EV / Sales 2027 * 13.4x
Free-Float
73.33%
Yield 2026 *
-
Yield 2027 * -
1 day+5.06%
1 week+12.95%
Current month+17.84%
1 month+64.65%
3 months+136.38%
6 months+69.78%
Current year+98.37%
1 week 13.52
Extreme 13.52
16.15
1 month 9.52
Extreme 9.5172
16.15
Current year 4.96
Extreme 4.955
16.15
1 year 3.84
Extreme 3.84
16.15
3 years 0.89
Extreme 0.8906
16.15
5 years 0.89
Extreme 0.8906
23.04
10 years 0.89
Extreme 0.8906
53.46
Manager TitleAgeSince
Chief Executive Officer 57 01/03/2023
President 55 12/03/2026
Chief Executive Officer 65 30/12/2022
Director TitleAgeSince
Director/Board Member 79 30/04/2019
Chairman 76 16/05/2022
Director/Board Member 72 05/03/2021
Date Insider Type Main position Quantity % Market Cap.
07-08Fiscal year

Chief Executive Officer

300,000 0.2865%
06-28Fiscal year

Chief Financial Officer

14,946 0.0143%
06-25Fiscal year

Chief Executive Officer

300,000 0.2865%
Change 5-day change 1-year change 3-year change Capi.($)
+5.06%+12.95%+144.05%+681.68% 1.57B
-0.17%+1.22%+2.98%+6.80% 50.35B
-0.29%-3.16%+380.69%+591.82% 39.32B
-0.49%-0.68%+29.15%-6.46% 34.69B
+1.53%+0.74%+23.45%+58.54% 34.08B
+1.68%-1.40%+4.23%+27.34% 26.63B
+1.13%+0.60% - - 16.49B
-1.29%-3.12%+65.20%+117.60% 15.31B
+0.43%+0.55%+15.19%+17.46% 13.8B
+2.45%+1.99%+15.09%-30.12% 12.87B
Average +1.00%+0.39%+75.56%+162.74% 24.51B
Weighted average by Cap. +0.43%-0.27%+81.67%+126.15%

Financials

2026 *2027 *
Net sales 78.74M 68.68M 63.38M 58.15M 111M 7.58B 112M 755M 296M 3.7B 296M 289M 12.76B 111M 96.82M 89.36M 81.99M 156M 10.68B 158M 1.06B 418M 5.22B 417M 408M 18B
Net income -107M -93.63M -86.41M -79.28M -151M -10.33B -153M -1.03B -404M -5.05B -403M -394M -17.4B -97.42M -84.97M -78.42M -71.95M -137M -9.38B -139M -934M -367M -4.58B -366M -358M -15.79B
Net Debt -178M -155M -143M -131M -249M -17.09B -254M -1.7B -669M -8.35B -667M -652M -28.79B -91.04M -79.4M -73.28M -67.23M -128M -8.76B -130M -873M -343M -4.28B -342M -334M -14.76B
Logo Personalis, Inc.
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
Employees
260
Date Price Change Volume
15/07/26 US$15.79 +5.06% 4,991,291
14/07/26 US$15.03 -0.07% 3,497,655
13/07/26 US$15.04 +6.89% 10,668,223
10/07/26 US$14.07 -3.96% 3,786,215
09/07/26 US$14.65 +3.83% 5,512,624
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
15.03USD
Average target price
11.43USD
Spread / Average Target
-23.96%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PSNL Stock